13 news items
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
ACIU
TAK
13 May 24
) announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer's disease
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
-to-Mid 30s% Target
Takeda (TYO
ean8fjyu
TAK
26 Apr 24
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless
ekqi9y4spsiccqxlz372kr6bfqcm5267j3
TAK
26 Apr 24
in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over
lpnyhm2jr2tfw54 1p1jrjebe
TAK
18 Apr 24
regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without
wwlw7wfks5xxpy0i
TAK
27 Mar 24
Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We
5841le8h84h6dz4fpggw61d1epxdf8 qca
TAK
19 Mar 24
− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (ALL
kd9y54egqxgdwxem8lbwq6mka
TAK
13 Mar 24
statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets
jo438he6xvgvexeplpzio 4f8
TAK
26 Feb 24
of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets
t9c316sxtkxpw00x 63
TAK
26 Feb 24
, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies
- Prev
- 1
- Next